September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Updates in the Use of Liquid Biopsies for Multiple Tumor Types
July 12th 2018Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.
Watch
Patel Considers a New Standard of Care When Treating Patients With NSCLC
July 6th 2018Jyoti D. Patel, MD, recently shared the treatment considerations and decisions she makes when treating patients with non–small cell lung cancer. Patel, professor of medicine and director of thoracic oncology at the University of Chicago Medicine in Illinois, discussed her treatment considerations for patients with NSCLC based on case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
Read More
Choosing Between Atezolizumab and Pembrolizumab in Lung Cancer
July 2nd 2018H. Jack West, MD, thoracic oncologist at the Swedish Cancer Institute of Swedish Medical Center, discusses the data with atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). West says that the choice of treatment is likely best left to the judgement of the physician and patient.
Watch
A Look Back at FDA News in June
July 2nd 2018The FDA approved several indications in the month of June, including venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), the combination of binimetinib (Mektovi) plus encorafenib (Braftovi) in melanoma, and bevacizumab (Avastin) in ovarian cancer. The FDA also accelerated approvals for pembrolizumab (Keytruda) in cervical cancer and in primary mediastinal large B-cell lymphoma, while also granting a priority review to glasdegib for acute myeloid leukemia.
Read More
Frontline Pembrolizumab Regimen Granted Priority Review by FDA for Squamous NSCLC
July 2nd 2018A supplemental biologics license application for first-line pembrolizumab (Keytruda) for use in combination with carboplatin/paclitaxel or nab-paclitaxel (Abraxane) has been granted a priority review by the FDA for the treatment of patients with metastatic squamous non–small cell lung cancer, regardless of PD-L1 expression.
Read More
Expert Provides Insight on Shifting SCLC Treatment Landscape
July 2nd 2018Immunotherapy may provide an opportunity to change the treatment paradigm of small cell lung cancer as new clinical trials report out in the next year, says Anne Chiang, MD, PhD. Recent results with immunotherapy agents in the second-line setting have already influenced guidelines.
Read More
Survival Improved With Atezolizumab Combo in Frontline SCLC
June 26th 2018Overall survival and progression-free survival were improved with the combination of frontline atezolizumab with chemotherapy compared with chemotherapy alone in patients with extensive-stage small cell lung cancer, meeting the coprimary endpoints of the phase III IMpower133 trial.
Read More